Call us free on 0800 862 0373

Sign in to view your quotes
Email address:
Password or PIN:

Forgotten your password? Reset it here.

NHS set to reject expensive new cancer drug Kadcyla

Published on 23/04/2014

The NHS is set to reject the use of the pioneering new breast cancer drug trastuzumab emtansine because the £90,000 cost is unjustifiable.

The cost of Kadcyla is deemed too much

The National Institute for Health and Care Excellence (NICE) sets the guidelines for England and Wales and has deemed the cost too high to justify its use on the NHS.

Campaigners are urging the pharmaceutical giant Roche to lower the cost of their drug but Roche say the price is appropriate for the amount of work in researching the drug.

The drug can add months of life to women dying of breast cancer and is currently available in England via the government’s Cancer Drugs Fund.

The Cancer Drug Fund is due to terminate in 2016 and NHS patients may no longer be able to have access to trastuzumab emtansine.

It is estimated that up to 20% of all breast cancer patients could benefit from trastuzumab emtansine treatment. The drug has been designed for women with HER2-receptor-positive cancer that has spread to other parts of the body.

The drug works by identifying and destroying cancerous cells by attacking them from within. By using this method it is unlikely to produce side effects linked to other forms of chemotherapy such as hair loss.

Trials of trastuzumab emtansine in women showed that participants who took the drug extended their lives by six months. The drug has been marketed under the brand name Kadcyla.

Consultant ooncologist, Professor Paul Ellis, at King’s College London has been administering his patients with the new drug.

He said: “Kadcyla represents a significant advance in HER2-positive breast cancer, so for NICE to issue negative preliminary guidance is a huge blow."

Sir Andrew Dillon, NICE chief executive, said: "We had hoped that Roche would have recognised the challenge the NHS faces in managing the adoption of expensive new treatments by reducing the cost of Kadcyla to the NHS.

"We hope the manufacturer will act in the best interests of patients and use this consultation period to look again at their evidence and consider if there is more they can do."

Private health insurance can give you access to the latest drugs and treatments not available on the NHS as part of your policy.

© ActiveQuote Ltd. 2014

Categories:  Health InsuranceHealthMedical
NHS set to reject expensive new cancer drug KadcylaThe NHS is set to reject the use of the pioneering new breast cancer drug trastuzumab emtansine because the £90,000 cost is unjustifia    tweet it on twittershare with your friends on Facebookshare with your friends on MySpaceBlog it on your LinkedIn profile

No.1 health insurance broker as rated by customers

Proactive, efficient, and offered me insurance I need. I would say half price I would end up paying if I did it by myself. Many thanks.

Review centre member

Excellent service. Explained everything in detail and really helped to find the right insurance best suited to my needs - which wasn't necessarily the most expensive. 

Review centre member

Good value and the advisor was very helpful and recommended the best policy for my grandson. I would definitely use this service again and recommend to others.

Review centre member

We were contacted in good time to make a knowledgable choice. We were given plenty of options with lots of information to enable us to make the right choice.

Review centre member

The service I received was excellent, the staff member was very efficient and knowledgable. She went out of her way to get the best policy for me.

Review centre member

Great service. I really appreciated the help provided by Active Quote to arrange health insurance. The agent was very informative and proactive. Many thanks!

Review centre member

I received excellent care and attention from the first phone call till the last. Friendly, efficient and patient.

Review centre member

Staff are very helpful, friendly and polite. They call back when they say they will and keep you up to date with progress. Pleasure to deal with.

Review centre member

Very polite and friendly, and gave detailed explanations of all aspects of the cover. Reassuring to know that if you do have a problem there is someone you can contact.

Review centre member

Friendly and efficient. Nothing was too much trouble even when i needed to make a small change, excellent service.

Review centre member
This site is operated by Insurance Broker ActiveQuote Ltd registered in England & Wales company number 6765845.
Authorised and Regulated by the Financial Conduct Authority (FCA). Firm reference number 501109 as detailed on the Financial Services Register. Please read our Key Facts document.
For information about your rights as a consumer visit Citizens Advice.

Our insurance comparison service is free and easy for you to use, but you are responsible for making sure all your information is entered correctly, and for choosing your insurer.

This site uses cookies in order to work correctly - these are not harmful and do not contain personal information. By using this site you consent to this. I understand  Tell me more

please wait ...